Initial dose escalation studies of the KRAS G12C inhibitors sotorasib and adagrasib were carried out pan-cancer, laying the groundwork for their accelerated approval in NSCLC (Hong et al. 2020, Ou et al. 2022). Here, KRAS is linked to non-small cell lung carcinoma.